CHEMIOTERAPIA NEL PAZIENTE ANZIANO CON CARCIOMA DELLA PROSTATA METASTATICO RESISTENTE ALLA CASTRAZIONE: CASO CLINICO
A. Gernone
Vol.2 (2017), issue 3, pag.14-18

Received 27/07/2017
Accepted for pubblication 04/08/2017
Published Sept. 2017
Review by Single-blind
jQuery UI Dialog - Animation

The care of elderly patients with metastatic castration resistant prostate cancer (mCRPC) is a therapeutic challenge. Retrospective data from phase III clinical trials, evidenced that chemotherapy with docetaxel or cabazitaxel might be selected as treatment options for ft-aged patients with mCRPC. Here we present the case of an elderly 90-years (2013) old male who was diagnosed with mCRPC in 2006. He received, from October 2007 to September 2013, Docetaxel as frst line of chemotherapy and cabazitaxel after progression on docetaxel-ba- sed chemotherapy. Both treatments were well tolerated without side effects.